KATHERINE
Switching to an ADC after surgery when pre-surgery treatment left cancer behind halved the risk of recurrence and improved survival.
3-year iDFS 88.3% vs 77.0% (HR 0.50); 7-year iDFS 80.8% vs 67.1%; OS HR 0.66 (7-year OS 89.1% vs 84.4%). Established the 'response-adapted' post-neoadjuvant paradigm now being upgraded by T-DXd (DESTINY-Breast05).
- 88.3 vs 77 out of 100 alive without the cancer coming back at 3 years with T-DM1 compared with Trastuzumab; 11.3 more per 100.
- Roughly one extra person helped for every 9 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 50 percent lower chance of the event at any given time (hazard ratio 0.5, likely range 0.39 to 0.64).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 89.1 vs 84.4 out of 100 alive at 7 years with T-DM1 compared with Trastuzumab; 4.7 more per 100.
- Roughly one extra person helped for every 21 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 34 percent lower chance of the event at any given time (hazard ratio 0.66, likely range 0.51 to 0.87).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: HER2+ early breast cancer with residual invasive disease after neoadjuvant therapy: T-DM1 vs trastuzumab for 14 cycles. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,486 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 3-year invasive disease-free survivalprimary | T-DM1 | 743 | 88.3% | 0.5 (0.39–0.64) | <0.001 | link |
| Trastuzumab | 743 | 77% | ||||
| Overall survival (7-year) | T-DM1 | — | 89.1% | 0.66 (0.51–0.87) | — | link |
| Trastuzumab | — | 84.4% |
Pages like this
not linked directly; found by shared links- Key paperKATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment
Shares Gunter von Minckwitz, Charles E. Geyer Jr., Trastuzumab emtansine, Pathologic complete response (pCR).
- TrialHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)
Shares Charles E. Geyer Jr., NSABP Foundation, Trastuzumab, HER2-positive breast cancer.
- InstitutionGerman Breast Group (GBG)
Shares Gunter von Minckwitz, NSABP Foundation, Pathologic complete response (pCR).
- TrialAPHINITY
Shares HER2-positive (IHC 3+ or ISH-amplified), Trastuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-02
- TrialPHERGain
Shares Pathologic complete response (pCR), Trastuzumab, HER2-positive breast cancer.
- IdeaCan T-DXd alone cure early HER2-positive disease?
Shares Pathologic complete response (pCR), Trastuzumab, HER2-positive breast cancer.
- TrialDESTINY-Breast05